Initial treatment response among HIV subtype F infected patients who started antiretroviral therapy based on integrase inhibitors
Open Access
- 2 January 2018
- journal article
- research article
- Published by Wolters Kluwer Health in AIDS
- Vol. 32 (1) , 121-125
Abstract
HIV-1 subtype B (54.4%) and subtype F (27.2%) are the most prevalent variants in patients who started antiretroviral therapy including an integrase inhibitor in the last 2 years in Northwest Spain. Virological response rates to antiretroviral therapy based on integrase inhibitor were significantly lower among F subtypes compared with B subtypes at weeks 12 (25.0% vs. 75.0%) and 24 (59.1% vs. 95.0%). Subtype F was independently associated with virological response at 24 weeks [odds ratio 11.8 (95% confidence interval 1.1–119.9); P = 0.037].Keywords
This publication has 17 references indexed in Scilit:
- Differences among HIV-1 subtypes in drug resistance against integrase inhibitorsInfection, Genetics and Evolution, 2016
- Molecular epidemiology of HIV-1 infection in Europe: An overviewInfection, Genetics and Evolution, 2016
- Trends on epidemiological, virological, and clinical features among newly diagnosed HIV‐1 persons in Northwest Spain over the last 10 yearsJournal of Medical Virology, 2015
- Molecular characterization of HIV-1 infection in Northwest Spain (2009–2013): Investigation of the subtype F outbreakInfection, Genetics and Evolution, 2015
- High prevalence of subtype F in newly diagnosed HIV-1 persons in northwest Spain and evidence for impaired treatment responseAIDS, 2014
- Most HIV Type 1 Non-B Infections in the Spanish Cohort of Antiretroviral Treatment-Naïve HIV-Infected Patients (CoRIS) Are Due to Recombinant VirusesJournal of Clinical Microbiology, 2012
- Clinical efficacy of raltegravir against B and non-B subtype HIV-1 in phase III clinical studiesAIDS, 2011
- Resistance associated mutations to dolutegravir (S/GSK1349572) in HIV-infected patients – Impact of HIV subtypes and prior raltegravir experienceAntiviral Research, 2011
- The SnoB study: frequency of baseline raltegravir resistance mutations prevalence in different non-B subtypesMedical Microbiology and Immunology, 2011
- Lack of Primary Mutations Associated With Integrase Inhibitors Among HIV-1 Subtypes B, C, and F Circulating in BrazilJAIDS Journal of Acquired Immune Deficiency Syndromes, 2009